Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

TERT

10 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Exploring the Role of TERT Promoter Mutations in Advanced Melanoma Treated With BRAF/MEK Inhibitors or Immune Checkpoint Inhibitors

Marchese PV, Zannini I, DE Biase D, et al.

Anticancer research

This retrospective single-center study investigated the role of TERT promoter mutations as a biomarker to guide treatment in advanced melanoma, particularly in BRAF V600 mutant patients. TERT mutations were detected in 73% of 159 patients and frequently co-occurred with BRAF V600 mutations. While TERT status was not an independent prognostic factor, exploratory analyses suggested a potential interaction with treatment type. Patients with BRAF/TERT co-mutations showed longer overall survival when treated with immune checkpoint inhibitors, whereas the opposite trend was observed for TERT wild-type patients receiving BRAF/MEK inhibitors. These preliminary findings warrant further validation in prospective studies.

Clinical · Molecular biology · Bioinfo & AI

Deep molecular profiling of lung neuroendocrine tumours and supra-carcinoids

Sexton-Oates A, Mathian É, Candeli N, et al.

Molecular cancer

This study conducted deep multi-omic analyses on over 300 lung neuroendocrine tumours (NETs) and supra-carcinoids, integrating whole-genome sequencing, transcriptome profiling, and DNA methylation arrays. Researchers identified four strikingly different molecular groups, varying in patient characteristics, genomic and transcriptomic profiles, microenvironment, and morphology. A new molecular group, enriched for highly aggressive supra-carcinoids with an immune-rich microenvironment linked to tumor-macrophage crosstalk, was discovered. This morpho-molecular classification unifies previous proposals and offers potential implications for prognosis and therapeutic management, particularly through the identification of group-specific therapeutic targets such as DLL3, EGFR, FGFR, and TERT.

Clinical · Molecular biology

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine

Crane K, Bhat KRS, Grivas P, et al.

Oncotarget

This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.

Clinical · Molecular biology

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study

Hartley HE, Fong FC, Gabriel AS, et al.

JCO precision oncology

This international study aimed to identify genetic prognostic biomarkers in a specific subgroup of intermediate-risk neuroblastoma patients, over 18 months old, without MYCN amplification, with localized unresectable or stage 3 tumors, and unfavorable histology, who experience poorer outcomes. Researchers analyzed chromosomal copy number alterations, next-generation DNA sequencing, telomere maintenance mechanisms, and gene expression. The findings revealed that oncogene amplifications, p53 pathway alterations, and typical segmental chromosomal aberrations (tSCAs) are independent prognostic markers associated with significantly reduced event-free and overall survival. These discoveries suggest that these patients might benefit from intensified or alternative treatments.

Clinical · Molecular biology

Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study

Cengiz A, Yıldızhan S, Rakip U, et al.

Neurological sciences

This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.

Bioinfo & AI

The Performance of In Silico Prediction Tools for Variant Curation in a Panel of Cancer Genes

Nelson N, Niaz A, Fairfax K, et al.

Human mutation

This study assesses the performance of in silico prediction tools for genetic variant curation within a panel of cancer predisposition genes. Researchers applied ClinGen SVI Working Group recommended thresholds and AlphaMissense predictions to variants in genes such as BRCA1, BRCA2, TP53, TERT, and ATM, which have established pathogenicity or benignity. The findings indicated insufficient sensitivity for pathogenic TERT variants and benign TP53 variants. The study emphasizes that the performance of these tools can be gene-specific and is influenced by their training datasets. Consequently, it is crucial to validate these tools for individual genes, especially for missense variants.

Clinical · Molecular biology

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations

Seifert AM, Richter S, Sagerer A, et al.

Journal of neuro-oncology

This study compared clinical characteristics and survival between molecularly defined IDH-wild-type glioblastoma (MolGBM) and histologically defined IDH-wild-type glioblastoma (HistGBM). It also characterized lower-grade IDH-wild-type astrocytic tumors lacking glioblastoma-defining genomic alterations. MolGBM exhibited a more favorable adjusted overall survival (HR 0.40) compared to HistGBM, particularly in patients aged 60 years or older. These findings highlight the clinical and biological heterogeneity among molecularly defined IDH-wild-type diffuse gliomas and the critical role of comprehensive molecular characterization. Lower-grade IDH-wild-type astrocytic tumors without glioblastoma-defining alterations warrant further in-depth molecular investigation.

Molecular biology

Sensitive detection of somatic mutations in GC-rich cancer gene promoters

Qi M, Dave PS, Francis N, et al.

NAR cancer

Somatic mutations in GC-rich promoter regions are significant drivers of cancer, yet their detection is challenging due to poor sequencing coverage in these areas. This study introduces a hybrid capture assay optimized for over 3000 cancer gene promoters, enabling deep sequencing of these complex regions. This method facilitates the discovery of reliable point mutations, short insertions/deletions, copy number variants, and mutational signatures. The assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer, paving the way for future functional follow-up.

Clinical · Molecular biology

The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors

Braat J, Trichy NS, Holic LJ, et al.

Human pathology

This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.

Molecular biology

PAX8-positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles - A clinicopathologic study of 101 consecutive cases with next-generation sequencing in 20 cases

Lammert SM, Luo W, Zhu AC, et al.

Histopathology

This retrospective study investigated the frequency and molecular profiles of PAX8-positive conventional urothelial carcinomas (UCs) of the urinary bladder. Out of 101 cases, 10% were found to be PAX8-positive by immunohistochemistry. Next-generation sequencing (NGS) was performed on 20 cases, including all PAX8-positive UCs. The findings revealed that PAX8-positive UCs frequently harbored TERT promoter mutations, TSC1 alterations, NOTCH1 loss, and WT1 loss, while notably lacking RB1 loss, distinguishing them from PAX8-negative UCs. These results indicate a distinct molecular signature for PAX8-positive UCs, emphasizing the need for careful diagnostic interpretation of PAX8.